Cargando…
The South West Area Mesothelioma and Pemetrexed trial: a multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication
BACKGROUND: Robust markers that predict prognosis and detect early treatment response in malignant pleural mesothelioma (MPM) would enhance patient care. METHODS: Consecutive patients with MPM who were considered fit for first-line chemotherapy were prospectively recruited. Patients of similar perfo...
Autores principales: | Hooper, C E, Lyburn, I D, Searle, J, Darby, M, Hall, T, Hall, D, Morley, A, White, P, Rahman, N M, De Winton, E, Clive, A, Masani, V, Arnold, D T, Dangoor, A, Guglani, S, Jankowska, P, Lowndes, S A, Harvey, J E, Braybrooke, J P, Maskell, N A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385956/ https://www.ncbi.nlm.nih.gov/pubmed/25756396 http://dx.doi.org/10.1038/bjc.2015.62 |
Ejemplares similares
-
The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial
por: Arnold, D T, et al.
Publicado: (2015) -
A Randomised Controlled Trial of Intravenous Zoledronic Acid in Malignant Pleural Disease: A Proof of Principle Pilot Study
por: Clive, Amelia O., et al.
Publicado: (2015) -
Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma
por: Ceresoli, G L, et al.
Publicado: (2013) -
The role of folate receptor alpha (FRα) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy
por: Nutt, J E, et al.
Publicado: (2010) -
Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma
por: Arnold, David T, et al.
Publicado: (2015)